Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKCANASDAQ:ARVNNASDAQ:FTSVNASDAQ:INSMNASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AARVNArvinas$7.89-0.1%$7.30$5.90▼$34.11$580.28M2.171.46 million shs826,658 shsFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AINSMInsmed$98.50+0.3%$80.87$60.40▼$106.83$18.55B0.92.31 million shs1.76 million shsPCRXPacira BioSciences$23.210.0%$25.17$11.16▼$27.64$1.07B0.48915,165 shs202,316 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ARVNArvinas0.00%+4.66%+13.54%+20.29%-66.98%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%INSMInsmed0.00%-1.00%+33.67%+42.38%+58.87%PCRXPacira BioSciences0.00%-1.17%-13.99%+0.45%+7.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AARVNArvinas3.1128 of 5 stars4.32.00.00.00.02.51.3FTSVForty SevenN/AN/AN/AN/AN/AN/AN/AN/AINSMInsmed4.162 of 5 stars2.54.00.04.33.51.70.6PCRXPacira BioSciences3.4579 of 5 stars2.22.00.03.92.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKCAAkcea Therapeutics 0.00N/AN/AN/AARVNArvinas 2.55Moderate Buy$20.29157.12% UpsideFTSVForty Seven 0.00N/AN/AN/AINSMInsmed 3.00Buy$106.808.43% UpsidePCRXPacira BioSciences 2.33Hold$26.4413.96% UpsideCurrent Analyst Ratings BreakdownLatest INSM, AKCA, FTSV, PCRX, and ARVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $112.006/11/2025INSMInsmedMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.006/11/2025INSMInsmedRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.006/11/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.006/11/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.006/11/2025INSMInsmedBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$94.00 ➝ $109.006/11/2025INSMInsmedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$90.00 ➝ $120.006/10/2025INSMInsmedJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/10/2025INSMInsmedCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy6/10/2025INSMInsmedLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$100.00 ➝ $115.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14ARVNArvinas$263.40M2.19N/AN/A$8.17 per share0.97FTSVForty Seven$15.68M293.33N/AN/A$7.52 per share12.70INSMInsmed$363.71M51.38N/AN/A$1.60 per share61.56PCRXPacira BioSciences$700.97M1.53$4.31 per share5.38$16.86 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/AARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)FTSVForty Seven-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/AINSMInsmed-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.28N/A9.03N/A-14.78%13.78%7.00%7/29/2025 (Estimated)Latest INSM, AKCA, FTSV, PCRX, and ARVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025ARVNArvinas-$0.87N/AN/AN/A$34.42 millionN/A7/29/2025Q2 2025PCRXPacira BioSciences$0.73N/AN/AN/A$183.11 millionN/A5/8/2025Q1 2025INSMInsmed-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKCAAkcea TherapeuticsN/A12.1711.78ARVNArvinasN/A4.584.58FTSVForty SevenN/A14.8114.81INSMInsmed11.385.865.44PCRXPacira BioSciences0.482.411.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKCAAkcea Therapeutics19.27%ARVNArvinas95.19%FTSVForty Seven71.77%INSMInsmedN/APCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipAKCAAkcea Therapeutics1.50%ARVNArvinas4.73%FTSVForty Seven37.40%INSMInsmed3.00%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableARVNArvinas42072.99 million69.54 millionOptionableFTSVForty Seven5748.16 millionN/ANot OptionableINSMInsmed1,271189.71 million184.02 millionOptionablePCRXPacira BioSciences72046.29 million43.33 millionOptionableINSM, AKCA, FTSV, PCRX, and ARVN HeadlinesRecent News About These CompaniesPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3 at 4:01 PM | globenewswire.comRobeco Institutional Asset Management B.V. Purchases 12,750 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)July 2 at 4:01 AM | marketbeat.comPacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025June 18, 2025 | finance.yahoo.comIs the Options Market Predicting a Spike in Pacira BioSciences Stock?June 18, 2025 | zacks.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Hold" from AnalystsJune 18, 2025 | marketbeat.comPACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 17, 2025 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Assenagon Asset Management S.A.June 14, 2025 | marketbeat.comGAMMA Investing LLC Grows Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)June 14, 2025 | marketbeat.comPacira Pharmaceuticals Stockholders Approve Amended Incentive PlanJune 13, 2025 | tipranks.comBridge City Capital LLC Reduces Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)June 9, 2025 | marketbeat.comPacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationJune 8, 2025 | accessnewswire.comAUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 21,781 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)June 8, 2025 | marketbeat.comLauren Riker Sells 5,578 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) StockJune 7, 2025 | insidertrades.comPacira BioSciences (NASDAQ:PCRX) Upgraded at Wall Street ZenJune 6, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) SVP Sells $146,199.38 in StockJune 6, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comPacira BioSciences’s First Quarter 2025 Misses EstimatesMay 29, 2025 | ryortho.comRBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach OutMay 25, 2025 | accessnewswire.comAPacira at RBC Conference: Strategic Growth and Gene Therapy FocusMay 23, 2025 | uk.investing.comPacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57%May 22, 2025 | finance.yahoo.comPacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare ConferencesMay 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeRussell Rebalance: 3 Stocks Ready to Move HigherBy Chris Markoch | June 20, 2025View Russell Rebalance: 3 Stocks Ready to Move HigherINSM, AKCA, FTSV, PCRX, and ARVN Company DescriptionsAkcea Therapeutics NASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Arvinas NASDAQ:ARVN$7.89 -0.01 (-0.11%) Closing price 07/3/2025 02:37 PM EasternExtended Trading$7.96 +0.07 (+0.87%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Forty Seven NASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Insmed NASDAQ:INSM$98.50 +0.26 (+0.26%) Closing price 07/3/2025 03:07 PM EasternExtended Trading$98.50 0.00 (0.00%) As of 07/3/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Pacira BioSciences NASDAQ:PCRX$23.20 -0.01 (-0.02%) As of 07/3/2025 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.